Heart failure & cardiomyopathies
Prevalence of Anti-Beta-1 Antibody 6 Months After Hospitalization for Acute Heart Failure Predicts Adverse Outcome
Main finding · Death or first HF hospitalisationResult — go to the resultHazard ratio 8.96 95% CI 1.81–44.50Authors' conclusion
Our results suggest a possible adverse prognostic relevance of b1-AAB in patients with acute HF, but this observation needs to be confirmed in larger patient collectives.
Study context
- Population
- Patients hospitalised for acute heart failure (HF)
- Participants
- 47 patients
- Exposure
- b1-AAB present vs absent at 6 months
- b1-AAB at F6n = 8
- Outcome
- Death or first hospitalisation for HF
- Follow-up
- 12 months after F6 (up to month 18)
Main finding
Death or first HF hospitalisation · up to month 18
Hazard ratio
8.96
95% CI 1.81–44.50
P = 0.007
b1-AAB at F6vs No b1-AAB at F6
HR 8.96 (95% CI 1.81–44.50); P = 0.007
As reported in the abstract
- Events during 12 months after F6
- 8
Observational data: associations, not effects.
Further findings
Prevalence of b1-AAB
- At index hospitalisation
- 3 (6%)
- At F6
- 8 (17%)
Baseline characteristics by b1-AAB at F6
- No differences in age, sex, type, duration or main cause of HF
Original publication
Prevalence of Anti-Beta-1 Antibody 6 Months After Hospitalization for Acute Heart Failure Predicts Adverse Outcome. ESC Heart Fail. Published 8 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →